S
Seigo Ishino
Researcher at Takeda Pharmaceutical Company
Publications - 22
Citations - 1162
Seigo Ishino is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Receptor & Vulnerable plaque. The author has an hindex of 13, co-authored 22 publications receiving 1104 citations. Previous affiliations of Seigo Ishino include Kyoto University & Kyoto Prefectural University of Medicine.
Papers
More filters
Journal Article
18F-FDG Accumulation in Atherosclerotic Plaques: Immunohistochemical and PET Imaging Study
Mikako Ogawa,Seigo Ishino,Takahiro Mukai,Daigo Asano,Noboru Teramoto,Hiroshi Watabe,Nobuyuki Kudomi,Masashi Shiomi,Yasuhiro Magata,Hidehiro Iida,Hideo Saji +10 more
TL;DR: The results suggest that macrophages are responsible for the accumulation of (18)F-FDG in atherosclerotic lesions, which should be useful for the selective detection of vulnerable plaques.
Journal Article
Application of 18F-FDG PET for Monitoring the Therapeutic Effect of Antiinflammatory Drugs on Stabilization of Vulnerable Atherosclerotic Plaques
Mikako Ogawa,Yasuhiro Magata,Takashi Kato,Kentaro Hatano,Seigo Ishino,Takahiro Mukai,Masashi Shiomi,Kengo Ito,Hideo Saji +8 more
TL;DR: Investigation of the usefulness of (18)F-FDG PET for monitoring therapies that target vascular inflammation found it useful for evaluating the therapeutic effect of drugs clinically and for the development of new drugs that can reduce inflammation of vulnerable plaques.
Journal ArticleDOI
Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors
Hirofumi Hanaoka,Takahiro Mukai,Takahiro Mukai,Hirokazu Tamamura,Hirokazu Tamamura,Tomohiko Mori,Seigo Ishino,Kazuma Ogawa,Yasuhiko Iida,Ryuichiro Doi,Nobutaka Fujii,Hideo Saji +11 more
TL;DR: Findings suggested that 111In-DTPA-Ac-TZ14011 would be a potential agent for the imaging of CXCR4 expression in metastatic tumors in vivo.
Journal ArticleDOI
Targeting of Lectinlike Oxidized Low-Density Lipoprotein Receptor 1 (LOX-1) with 99mTc-Labeled Anti–LOX-1 Antibody: Potential Agent for Imaging of Vulnerable Plaque
Seigo Ishino,Takahiro Mukai,Yuji Kuge,Noriaki Kume,Mikako Ogawa,Nozomi Takai,Junko Kamihashi,Masashi Shiomi,Manabu Minami,Toru Kita,Hideo Saji +10 more
TL;DR: Nuclear imaging of LOX-1 expression with 99mTc-LOX- 1-mAb may be a useful means for predicting atheroma at high risk for rupture.
Journal ArticleDOI
Comparison of Contrast Agents for Atherosclerosis Imaging Using Cultured Macrophages: FDG Versus Ultrasmall Superparamagnetic Iron Oxide
Tomoko Satomi,Mikako Ogawa,Ikuo Mori,Seigo Ishino,Kazuki Kubo,Yasuhiro Magata,Tomoyuki Nishimoto +6 more
TL;DR: Compared with M2, proatherogenic M1 macrophages preferentially accumulated FDG but not USPIO, suggesting that FDG PET is a useful method for the detection of proinflammatory M1macrophages.